Objective: Cholinergic neurons in the nucleus accumbens (NAc) express δ and μ receptors that are thought to inhibit neural activity (Britt & McGehee, 2008). δ and μ receptors are divided into δ 1 and δ 2 receptors and μ 1 and μ 2 receptors, respectively. Therefore, we analysed the roles of δ and μ receptor subtypes in regulating accumbal acetylcholine (ACh) efflux using in vivo microdialysis. Methods: Male Sprague-Dawley rats were used. ACh levels in accumbal perfusates, taken every 15 min, were determined by HPLC-ECD. Apart from the μ 1 receptor antagonist naloxonazine, which was given intraperitoneally, δ and μ receptor ligands were administered intracerebrally through the dialysis probe. Doses of these compounds indicate total amount (mol) over a 30-min infusion time. To monitor basal ACh levels, a low concentration of physostigmine (50 nM) was added to the perfusate. Results: The δ 1 receptor agonist DPDPE (3 and 300 pmol) and δ 2 receptor agonist deltorphin II (3 and 30 pmol) decreased accumbal ACh in a dose-related manner. DPDPE (300 pmol)-and deltorphin II (3 pmol)-induced reduction in ACh were each inhibited by co-administration of the δ 1 receptor antagonist BNTX (0.3 pmol) and δ 2 receptor antagonist NTB (15 pmol), respectively. The μ receptor agonists endomorphin (EM)-1 and EM-2 (6 and 30 nmol) decreased ACh in a dose-related manner. EM-1-and EM-2 (30 nmol)-induced reductions in ACh were prevented by co-administration of the μ receptor antagonist CTOP (3 nmol), which failed to alter basal ACh. Naloxonazine (15 mg/kg ip), which inhibits EM-1 (15 nmol)-induced accumbal dopamine efflux (Okutsu et al, 2006), did not alter EM-1 (30 nmol)-or EM-2 (30 nmol)-induced reductions in ACh.
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Abstract Background: Internet gaming disorder (IGD), as a behavioral addiction, shares clinical and neuropsychological features with alcohol use disorder (AUD), but few studies exist that identify neurophysiological characteristics in IGD. The aim of this study was to investigate N100 and P300 of auditory event-related potentials (ERPs) in patients with IGD and compare those with patients with AUD and healthy controls.
Methods:
Twenty-six patients diagnosed with IGD (22.69 ± 4.76 years), 22 patients diagnosed with AUD (28.36 ± 5.40), and 29 healthy controls (24.66 ± 3.80) participated in this study. Electroencephalography (EEG) scans were acquired during an auditory oddball task from all participants who were young adult males. Between-group differences in N100 and P300 were investigated using repeated measures analysis of variance, respectively. Results: Both the IGD and AUD groups showed significantly reduced P300 amplitudes at midline centro-parietal site compared with HCs. The IGD group also exhibited significantly reduced N100 amplitudes at midline fronto-central site compared with HCs. Reduced N100 and P300 amplitudes in the IGD group were not correlated with scores on Internet Addiction severity.
Conclusion:
These results indicate that IGD has abnormalities of P300 index which are comparable to those in AUD, and N100 amplitudes reduction could be considered as a candidate trait marker of IGD. This study enhances our understanding of neurophysiological characteristics of IGD which differentiate patients with IGD from those with AUD and healthy controls. Keywords: alcohol use disorder (AUD), auditory oddball task, event-related potential (ERP), Internet gaming disorder (IGD), N100, P300.
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Abstract Objective: To investigate the association between DNA methylation in peripheral blood cells and abstinence in alcoholics treated with acamprosate. Methods: Illumina Infinium 450k HumanMethylation BeadChip was utilized to assess the genome-wide methylation status of approximately 500,000 CpGs in 26 peripheral blood DNA samples collected from 13 subjects before and after 3 months of acamprosate treatment. A subset of 627 methylation probes was selected based upon variability within paired samples. Unsupervised hierarchical clustering and principal component analysis (PCA) were performed using this subset of probes, followed by tests of association of the resulting clusters and principal components with 3 month abstinence. Ingenuity Pathway Analysis (IPA) was used for functional assessment of the 54 most differentially methylated CpGs. Results: A DNA methylation signature based on 627 CpGs was associated (p=4.88E-04) with abstinence during acamprosate treatment. The samples clustered based upon sobriety vs. relapse, rather than acamprosate effect on the DNA methylation landscape. The association remained significant (adjusted p=4.73E-3) after adjustment for potential confounders (study site, number of days since last drink, and craving score). Separation of the methylation signatures from relapsers and abstainers was also confirmed by PCA analysis. Functional assessment with IPA showed enrichment for pathways including "Drug Metabolism", "Uptake of Dopamine" and "Neurological Disease". Moreover, one of the aberrantly methylated CpG is located in the 3' UTR of the SLC6A3 gene, encoding a dopamine transporter, which has been implicated in a variety of psychiatric disorders, alcoholism, and was also associated with an ability to quit smoking.
